728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors

Hamid, O., Sato, T., Davar, D., Callahan, M. K., Thistlethwaite, F., Aljumaily, R., Johnson, M. L., Arkenau, H.-T., Ileana Dumbrava, E. E., Izar, B., Chen, H. A., Marshall, S., Yuan, Y., Deo, M., Stanhope, S., Collins, L., Mundy, R., Abdullah, S. E., & Lopez, J. S. (2022). 728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Annals of Oncology, 33, S875. https://doi.org/10.1016/j.annonc.2022.07.854
Authors:
Omer Abdul Hamid
T. Sato
D. Davar
M.K. Callahan
F. Thistlethwaite
R. Aljumaily
M.L. Johnson
H-T. Arkenau
Ecaterina E. Dumbrava
B. Izar
H.A. Chen
S. Marshall
Y. Yuan
M. Deo
S. Stanhope
L. Collins
R. Mundy
Shaad E. Abdullah
J.S. Lopez
Affiliated Authors:
B. Izar
Subjects:
Therapeutic Antibodies: Development, Engineering, and Applications (OpenAlex Topic)
Development and Applications of Radiopharmaceuticals (OpenAlex Topic)
Glycosylation in Health and Disease (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2022.07.854
DOI:
10.1016/j.annonc.2022.07.854
Journal:
Annals of Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: